Impact of neutron sieve therapy for deep site in boron neutron capture therapy using Monte Carlo calculation
Clinical Snapshot
PICO Framework
| P — Population | Simulated human tissue phantoms representing patients with deep-seated tumours undergoing boron neutron capture therapy (BNCT) via an accelerator-based compact neutron generator (Fukushima SiC system) |
| I — Intervention | Neutron sieve filter configurations composed of 6LiF-plastic and polyethylene in sieve geometry, adapted from X-ray sieve therapy principles, applied to the BNCT beam |
| C — Comparator | Block filter configurations (polyethylene alone, 6LiF-plastic alone) and unmodified BNCT beam (no filter baseline) |
| O — Outcomes | Thermal neutron fluence depth distribution, maximum dose point depth shift (mm), percentage change in neutron fluence at specified depths (20 mm), and skin dose equivalence |
Bottom Line
This Monte Carlo simulation study investigates whether neutron sieve filters — adapted from an established X-ray radiotherapy technique — can improve depth dose distribution in accelerator-based boron neutron capture therapy (BNCT) using the Fukushima SiC compact neutron generator. The principal finding is that a combined 6LiF-plastic and polyethylene sieve filter shifts the maximum dose point approximately 8 mm deeper into tissue, with a 5.5% increase in thermal neutron fluence at 20 mm depth at equivalent skin dose. While the concept is innovative and the clinical problem — inadequate neutron penetration for deep-seated tumours — is genuine and important, the study is entirely preclinical and computational. Critical methodological details including the Monte Carlo code, statistical uncertainties, phantom specifications, and biological dose weighting are absent from the reported findings. The modest physical dosimetric gains have not been contextualised against radiobiological thresholds or tumour-to-normal tissue dose ratios. No experimental validation has been performed. For Australian clinicians, BNCT remains investigational with no TGA-approved systems or PBS-listed indications. This paper represents an early-stage proof-of-concept contribution that requires substantial further development — including physical validation, biologically weighted dosimetry, and clinical feasibility studies — before any clinical translation can be considered.
Key Findings
P Value: Not applicable — computational simulation study; no inferential statistics reported
Effect Size: Maximum dose point shifted 8 mm deeper using a combined 6LiF-plastic and polyethylene sieve filter; 5.5% increase in neutron fluence at 20 mm depth at equivalent skin dose
Primary Outcome: Thermal neutron fluence depth distribution modified by sieve and block filter configurations in a tissue phantom irradiated by the Fukushima SiC BNCT system
Nnt Or Sensitivity: Not applicable at this stage — no clinical outcome data available; dosimetric gain of 8 mm depth shift and 5.5% fluence increase at 20 mm requires biological weighting and clinical contextualisation before NNT or equivalent metrics can be derived
Confidence Interval: Not reported — no statistical uncertainty estimates provided
Clinical Application
Clinical implementation is not yet feasible. The study is entirely computational and requires: (1) physical phantom validation experiments, (2) biologically weighted dosimetry modelling, (3) treatment planning system integration, (4) regulatory approval for filter device use, and (5) prospective clinical dosimetry studies before any patient application. The sieve filter concept is mechanically straightforward but requires precise manufacturing tolerances for clinical use. BNCT is not currently available as a standard clinical service in Australia. The TGA has not approved any BNCT system for routine clinical use, and no PBS listing exists for BNCT. Australian research interest in BNCT is emerging, primarily through academic and nuclear medicine research groups. The Fukushima SiC system evaluated in this study is a Japanese device not deployed in Australia. RACGP and relevant specialist college guidelines (RANZCR) do not currently address BNCT. Australian clinicians should monitor international BNCT developments, particularly for recurrent glioblastoma and unresectable head and neck cancer, but this specific study has no immediate practice implications for Australian healthcare settings. Hypothetically applicable to patients with deep-seated tumours (e.g., glioblastoma, head and neck cancers, hepatic malignancies) being considered for accelerator-based BNCT, specifically those treated with the Fukushima SiC compact neutron generator system
Abstract
Recent Boron neutron capture therapy (BNCT) has shifted to accelerator-based systems. One of them is a compact neutron generator developed using silicon carbide (SiC) semiconductors by Fukushima SiC Applied Technology Co. However, neutron penetration remains a critical challenge for treating deep-seated tumors. This study investigated the potential of neutron sieve therapy, originally developed to enhance the depth dose distribution in X-ray therapy, to improve BNCT dose distribution via Monte Carlo simulations based on the Fukushima SiC BNCT system. Dose distribution changes were investigated using polyethylene and 6LiF-plastic in block and sieve shapes. The results show that the maximum thermal neutron fluence depth was shallower (deeper) with polyethylene (6LiF-plastic) filters. The sieve filter moderately altered the dose distribution compared to the block filter due to density differences. The maximum dose point shifted 8 mm deeper using a sieve filter composed of 6LiF-plastic and polyethylene, with a 5.5% increase at 20 mm depth in neutron fluence at the same skin dose.
References
- 1.Matsushita, K., Yamazaki, H., & Matsubara, H. (2026). Impact of neutron sieve therapy for deep site in boron neutron capture therapy using Monte Carlo calculation. Radiation Protection Dosimetry. https://doi.org/10.1093/rpd/ncag018
Related Research
Medical physics
Reference-Free large language model agents for physician-guided radiotherapy treatment planning
2 Aug 2026
Cancer medicine
Applications of Artificial Intelligence in Cancer Diagnosis and Treatment
1 Aug 2026
Acta oncologica (Stockholm, Sweden)
User perceptions of machine learning models as decision support for colorectal cancer multidisciplinary team conferences (AID-SIM-2): a qualitative simulation study.
1 Aug 2026
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service